Daily Cardiology Research Analysis
Three impactful cardiology studies span translational mechanisms and clinical implementation. Two Circulation papers reveal mechanistic drivers of myocardial injury and energetic failure—linking an East Asian ALDH2*2 variant to ferroptosis via selective mRNA translation and identifying oxidative CK dysfunction in hypertrophic cardiomyopathy. A large randomized trial shows telemedical secondary prevention after PCI significantly reduces MACCE at 1 year.
Summary
Three impactful cardiology studies span translational mechanisms and clinical implementation. Two Circulation papers reveal mechanistic drivers of myocardial injury and energetic failure—linking an East Asian ALDH2*2 variant to ferroptosis via selective mRNA translation and identifying oxidative CK dysfunction in hypertrophic cardiomyopathy. A large randomized trial shows telemedical secondary prevention after PCI significantly reduces MACCE at 1 year.
Research Themes
- Ferroptosis and genetic risk in acute myocardial infarction
- Energetic remodeling and CK dysfunction in hypertrophic cardiomyopathy
- Telemedicine-enabled secondary prevention post-PCI
Selected Articles
1. ALDH2/eIF3E Interaction Modulates Protein Translation Critical for Cardiomyocyte Ferroptosis in Acute Myocardial Ischemia Injury.
In a human cohort and complementary mouse models, ALDH2*2 carriers exhibited a ferroptosis signature and worse post-MI heart failure. Mechanistically, loss of ALDH2 permits eIF3E–eIF4G1–mRNA assembly and selective translation of GAGGACR motif-bearing transcripts (e.g., TFRC, ACSL4) that drive ferroptosis; inhibiting ferroptosis or knocking down eIF3E mitigated injury.
Impact: This study reveals a previously unrecognized translational control mechanism linking a common East Asian ALDH2 variant to cardiomyocyte ferroptosis after MI, providing genotype-informed therapeutic targets.
Clinical Implications: Suggests patient stratification by ALDH2 genotype and evaluation of ferroptosis-modulating therapies (e.g., lipid peroxidation and iron-handling pathways) after MI; supports exploration of eIF3E/translation-targeted interventions.
Key Findings
- ALDH2*2 carriers showed more severe post-MI heart failure with lipidomic features of ferroptosis (reduced CoQ10 and BH4).
- In ALDH2*2 MI mice, ferroptosis inhibition (Fer-1) improved cardiac function and reversed ferroptosis markers.
- ALDH2 interacts with eIF3E; ALDH2 deficiency frees eIF3E to assemble with eIF4G1, enabling selective translation of GAGGACR motif-bearing mRNAs (TFRC, ACSL4, UAP1) that drive ferroptosis; cardiomyocyte eIF3E knockdown rescued function.
Methodological Strengths
- Translational design integrating human cohort lipidomics with mechanistic mouse and cellular models.
- Causal perturbations using ferroptosis inhibitor and cardiomyocyte-specific eIF3E knockdown.
Limitations
- Population mainly East Asian; generalizability to other ancestries requires study.
- Therapeutic implications are preclinical; no randomized clinical validation.
Future Directions: Prospective trials testing ferroptosis-targeted therapies post-MI with ALDH2-genotype stratification; structural characterization of eIF3E–ALDH2 interfaces and small-molecule modulators.
BACKGROUND: As an iron-dependent form of regulated cell death caused by lipid peroxidation, ferroptosis has been implicated in ischemic injury, but the underlying mechanisms in acute myocardial infarction (AMI) remain poorly defined. ALDH2 (acetaldehyde dehydrogenase 2) catalyzes detoxification of lipid aldehydes derived from lipid peroxidation and acetaldehydes from alcohol consumption. The Glu504Lys polymorphism of ALDH2 (rs671, ALDH22), affecting ≈40% of East Asians, is associated with increased risk of myocardial infarction (MI). This study aims to investigate the role of ALDH22 and ferroptosis in AMI. METHODS: A Chinese cohort of 177 patients with acute heart failure with ALDH2 wild type and ALDH22 was enrolled. The MI mouse model of left anterior descending coronary artery ligation was conducted on wild-type and ALDH22 mice and mice with cardiomyocyte-specific knockdown of eIF3E (eukaryotic translation initiation factor 3 subunit E) by adeno-associated virus. The lipid peroxidation products were measured by mass spectrometry-based lipidomics and metabolomics in human plasma, mouse serum samples, mouse heart tissues, and primary cardiac myocytes. RESULTS: Human ALDH22 carriers exhibit more severe heart failure after AMI with features of ferroptosis in plasma, as seen through lipidomic analysis, characterized by increased bioactive lipids and decreased antioxidants, such as coenzyme Q10 and BH4 (tetrahydrobiopterin). Similar features were observed in MI mouse models of ALDH22, whereas ferroptosis inhibition by Fer-1 significantly improved heart function and reversed ferroptosis markers. Importantly, ALDH22 significantly decreased ALDH2 protein levels, whereas ferroptosis-related markers, including TFRC (transferrin receptor) and ACSL4 (acyl-coenzyme A synthetase long-chain family member 4) were notably upregulated in the infarct heart tissues. Mechanistically, ALDH2 physically interacts with the eIF3 complex via the eIF3E factor, which prevents eIF3E-eIF4G1 (eukaryotic initiation factor 4G)-mRNA assembly. The ALDH22 variant causes ALDH2 deficiency, disrupting its interaction with the eIF3 complex by releasing the bound eIF3E to assemble an eIF3E-eIF4G1-mRNA ternary complex, thereby driving selective translation of mRNAs (eg, TFRC, ACSL4, and UAP1) containing the GAGGACR (R represents A/G) motif to promote ferroptosis. Consistently, cardiomyocyte-specific eIF3E knockdown restored ALDH22 cardiac function by attenuating ferroptosis in MI. CONCLUSIONS: ALDH22 aggravates acute heart failure after MI by promoting the selective translation of mRNAs containing the GAGGACR motif, thereby driving cardiomyocyte ferroptosis. Targeting ferroptosis represents a potential therapeutic option for mitigating MI injury, especially for ALDH2*2 carriers.
2. Hypercontractility and Oxidative Stress Drive Creatine Kinase Dysfunction in Hypertrophic Cardiomyopathy.
Human HCM myocardium exhibited reduced myofilament and mitochondrial CK protein and activity, largely due to oxidative modifications. Hypercontractility increased mitochondrial ROS and aggravated CK dysfunction in experimental systems, supporting a vicious cycle of energetic failure that may be interrupted by myosin inhibition.
Impact: Connects hypercontractility-induced oxidative stress to CK dysfunction in HCM, reframing energy failure as a treatable mechanistic target and informing use of myosin inhibitors.
Clinical Implications: Supports therapeutic strategies that reduce hypercontractility and oxidative stress (e.g., myosin inhibitors) to restore myocardial energetics and potentially lower arrhythmic risk in HCM.
Key Findings
- Myofilament and mitochondrial CK protein levels and activity are reduced in HCM myocardium, primarily due to oxidative modifications.
- Hypercontractility elevates mitochondrial ROS, exacerbating CK dysfunction and energetic mismatch in experimental models.
- Data support targeting hypercontractility/oxidative stress (e.g., myosin inhibition) to restore energy homeostasis.
Methodological Strengths
- Large human myocardial tissue cohort with multi-omic and redox proteomic characterization.
- Mechanistic validation across cardiomyocyte models with genetic and pharmacologic perturbations.
Limitations
- Some methodological details truncated in abstract; full mechanistic pathway steps require full-text verification.
- Translational implications are inferential; no clinical outcome intervention tested.
Future Directions: Clinical studies to test whether myosin inhibition normalizes myocardial energetics and reduces arrhythmias; development of CK-protective antioxidant strategies targeted to myofilament/mitochondrial compartments.
BACKGROUND: Hypertrophic cardiomyopathy (HCM) is a prevalent inherited cardiac disorder marked by left ventricular hypertrophy and hypercontractility. This excessive mechanical workload creates an energetic mismatch in which consumption exceeds production, leading to myocardial energy depletion. Although CK (creatine kinase) plays a key role in cardiac energy homeostasis, its involvement in HCM remains unclear. This study investigates how hypercontractility-driven mitochondrial stress and the resulting increase in mitochondrial H METHODS: CK function was analyzed using myocardial left ventricular tissue from 92 patients with HCM (with and without pathogenic sarcomere variants) and 30 non-failing human controls. Myofilament and mitochondrial CK isoforms were measured using mRNA analysis, protein immunoblotting, enzyme activity assays, mass spectrometry, and redox-sensitive proteomics. To explore links between hypercontractility, mitochondrial reactive oxygen species, and CK dysfunction, we used isolated cardiomyocytes from wild-type, mitochondrion-targeted catalase-overexpressing, CK knockout (myofilament and mitochondrial CK deletion), HCM-associated RESULTS: Our analysis revealed significant reductions in myofilament and mitochondrial CK protein levels, as well as CK activity, in myocardium of patients with HCM, primarily because of oxidative modifications of CK. In isolated mouse cardiomyocytes from wild-type and CK knockouts, hypercontractility induced by EMD-57033 elevated mitochondrial H CONCLUSIONS: This study reveals a mechanistic link between hypercontractility, mitochondrial reactive oxygen species, and CK dysfunction in HCM, perpetuating a cycle of energetic dysfunction. Targeting hypercontractility and oxidative stress through myosin inhibition offers a strategy to restore energy balance and reduce arrhythmic risk in HCM.
3. Efficacy of Telemedical Interventional Management in Patients with Coronary Heart Disease Undergoing Percutaneous Coronary Intervention: Randomized Controlled Trial.
In a randomized, single-center trial of 2086 post-PCI patients, a multicomponent telemedicine program reduced 1-year MACCE (3.5% vs 5.3%), driven by lower cardiac death and MI, and improved BP control and medication adherence with fewer major bleeds.
Impact: Demonstrates that structured telemedical management can yield measurable reductions in hard cardiovascular outcomes after PCI while improving risk factor control at scale.
Clinical Implications: Supports implementing comprehensive telemedicine platforms for post-PCI secondary prevention with personalized education, monitoring, and adherence support; calls for multicenter validation.
Key Findings
- Telemedical care reduced 1-year MACCE (3.5% vs 5.3%; P=.04), notably cardiac death (1.0% vs 2.3%; P=.02) and MI (0.8% vs 1.8%; P=.03).
- BARC 3–5 bleeding was lower in the intervention group (0.6% vs 1.6%; P=.03).
- Improved systolic/diastolic BP, higher adherence to antiplatelets and RAASi/ARNI, and reduced alcohol use.
Methodological Strengths
- Large sample size randomized controlled design with hard clinical endpoints at 12 months.
- Multicomponent intervention with defined platform features and standardized follow-up.
Limitations
- Single-center, open-label design may limit generalizability and introduce performance bias.
- Lack of blinded adjudication and external validation across diverse healthcare settings.
Future Directions: Multicenter, pragmatic RCTs across varied health systems to confirm MACCE reduction and cost-effectiveness; dismantling studies to identify high-yield components of telemedicine programs.
BACKGROUND: Coronary heart disease (CHD) continues to be a leading cause of global morbidity and mortality, with patients undergoing percutaneous coronary intervention (PCI) facing a significant risk of recurrent cardiovascular events. While secondary prevention strategies, such as medication adherence and lifestyle modifications, are essential, implementation gaps remain due to limited health care access and inadequate patient engagement. Telemedical interventions offer a promising solution to these challenges by facilitating remote monitoring and providing individualized patient management strategies. OBJECTIVE: This randomized controlled trial aimed to evaluate the efficacy of a comprehensive web-based telemedical interventional management system in reducing major adverse cardiac and cerebrovascular events (MACCE) and enhancing secondary prevention outcomes among patients with CHD following PCI, compared to usual care alone. METHODS: We conducted a single-center, open-label, randomized controlled trial at a tertiary hospital in China. A total of 2086 patients with post-PCI CHD were randomly assigned in a 1:1 ratio to receive either telemedical management combined with usual care (intervention group; n=1040) or usual care alone (control group; n=1046). The control group received follow-up phone calls from health care providers at 1, 3, 6, and 12 months after discharge. In contrast, the remote patient management group benefited from multicomponent interventions delivered through a telemedicine platform, alongside usual care. This platform provided personalized health education, medication reminders, vital sign monitoring, and artificial intelligence-assisted consultations. The primary outcome was the composite incidence of MACCE, including cardiac death, myocardial infarction, stroke, or target vessel revascularization, at one year. Secondary outcomes included bleeding events, lifestyle changes, blood pressure control, and medication adherence. RESULTS: At the one-year follow-up, the intervention group demonstrated a significant reduction in MACCE compared to the control group (36/1040, 3.5% vs 55/1046, 5.3%, P=.04). This was primarily attributed to lower rates of cardiac death (10/1040, 1.0% vs 24/1046, 2.3%, P=.02) and myocardial infarction (8/1040, 0.8% vs 19/1046, 1.8%, P=.03). Additionally, bleeding events classified as BARC 3-5 were less frequent in the intervention group (6/1040, 0.6% vs 16/1046, 1.6%, P=.03). The intervention group also exhibited improved control over systolic blood pressure (mean 117.74, SD 13.80 mmHg vs mean 121.46, SD 16.85 mmHg, P=.002) and diastolic blood pressure (mean 73.60, SD 10.18 mmHg vs mean 75.72, SD 10.45 mmHg, P=.02), along with higher medication adherence to aspirin (896/1021, 87.8% vs 858/1017, 84.4%, P=.03) and angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or angiotensin receptor-neprilysin inhibitors (489/1021, 47.9% vs 442/1017, 43.5%, P=.045). Furthermore, there was a notable reduction in alcohol consumption among participants in the intervention group (119/1021, 11.7% vs 168/1017, 16.5%, P=.002), alongside a trend towards decreased smoking rates (114/1021, 11.2% vs 142/1017, 14.0%, P=.06). CONCLUSIONS: Telemedical interventional management significantly enhanced clinical outcomes by reducing MACCE and improving risk factor control among patients with CHD who underwent PCI. These findings underscore the potential of telemedicine to bolster secondary prevention efforts and long-term care strategies. Further multicenter studies are necessary to validate these results and optimize telemedicine frameworks for broader implementation.